,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2015', 'fs': 'Aug 2015', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4j8J2AR'}, 'Id': 'a0POZ00000B4j8J2AR', 'Event_Date__c': '2015-08-24', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Aug 2015', 'Status_History__c': 'a132P000000CAssQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2019', 'fs': 'Dec 2019', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4j8K2AR'}, 'Id': 'a0POZ00000B4j8K2AR', 'Event_Date__c': '2019-12-02', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Dec 2019', 'Status_History__c': 'a132P000000CpB9QAK'}, 'change': None}]",Aug 2015,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2020', 'fs': 'Jun 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4j8L2AR'}, 'Id': 'a0POZ00000B4j8L2AR', 'Event_Date__c': '2020-06-15', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jun 2020', 'Status_History__c': 'a132P000000CAt2QAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee <b>recommended</b> ibrutinib for the treatment of relapsed/refractory del11q CLL be declined, within the context of treatment of malignancy.</p><p style=""text-align: justify;"">1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee considered there to be no clear evidence that ibrutinib confers additional benefit in patients with the del11q mutation compared with the wider CLL patient population when making this recommendation.</p><p><br></p>', 'fs': '<p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee <b>recommended</b> ibrutinib for the treatment of relapsed/refractory del11q CLL be declined, within the context of treatment of malignancy.</p><p style=""text-align: justify;"">1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee considered there to be no clear evidence that ibrutinib confers additional benefit in patients with the del11q mutation compared with the wider CLL patient population when making this recommendation.</p><p><br></p>', 'change': None}, 'Published_Discussion': {'s': '<p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that the current treatment options for patients ineligible for fludarabine based chemoimmunotherapy (fludarabine ± cyclophosphamide and rituximab) were obinutuzumab-chlorambucil or bendamustine-rituximab, and noted that bendamustine-rituximab was not funded in the relapsed/refractory setting. The Subcommittee noted that if the patient had the 17p deletion or the TP53 mutation, that they would be eligible for venetoclax monotherapy as first line treatment. The Subcommittee noted that patients who relapse within 36 months of treatment with obinutuzumab-chlorambucil or bendamustine-rituximab would be eligible for venetoclax-rituximab. The Subcommittee noted that after venetoclax-rituximab, if patients have not received obinutuzumab, they would be eligible for this as third line treatment.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the current treatment options for patients eligible for fludarabine based chemoimmunotherapy (fludarabine ± cyclophosphamide and rituximab) was FCR, unless the patient had the 17p deletion or the TP53 mutation, in which case they would be eligible for venetoclax monotherapy. The Subcommittee noted that that patients who relapse within 36 months of treatment with FCR would be eligible for venetoclax-rituximab. The Subcommittee noted that after venetoclax-rituximab, if patients have not received obinutuzumab, they would be eligible for this as third line treatment.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><i>Ibrutinib for patients with relapsed/refractory del11q CLL</i></p><p style=""text-align: justify;""><span style=""color: black;"">1.3</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the current Special Authority for venetoclax in combination with rituximab includes patients with relapsed/refractory del 11q CLL. The Subcommittee noted that ibrutinib has not been specifically reviewed in this subpopulation previously.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the del11q mutation is present in 10-20% of patients with CLL, and that patients with del11q were considered to have shorter progression free survival (i.e. faster progression) that those without. The Subcommittee noted that data from the CLL8 trial reported this risk of faster progression is reversed with immunochemotherapy (<a href=""https://ashpublications.org/blood/article/127/2/208/34815/Long-term-remissions-after-FCR-chemoimmunotherapy"" target=""_blank"">Fischer et al. Blood. 2016;127:208-15</a>). The Subcommittee considered that, when treated with FCR, the overall survival of patients with the del11q mutation is not adversely reduced compared with patients with normal cytogenetics. The Subcommittee considered that there was little evidence that the del11q subgroup is a high risk subgroup with greater unmet health need when compared with the wider CLL population. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the results of a pooled analysis of the randomised RESONATE, RESONATE-2 and HELIOS trials, which reported that ibrutinib-treated patients with del11q had a significantly longer progression free survival than ibrutinib-treated patients without del11q (42-month progression free survival rate 70% vs. 65%, p=0.02) (<a href=""https://www.sciencedirect.com/science/article/pii/S2152265019303982?via%3Dihub"" target=""_blank"" style=""color: blue;"">Kipps et al.</a><a href=""https://www.sciencedirect.com/science/article/pii/S2152265019303982?via%3Dihub"" target=""_blank"" style=""color: windowtext;""> </a><a href=""https://www.sciencedirect.com/science/article/pii/S2152265019303982?via%3Dihub"" target=""_blank"" style=""color: blue;"">Clin Lymphoma Myeloma Leuk. 2019;19(11):715-22</a>). The Subcommittee noted that the comparators in these trials (ofatumumab, chlorambucil and bendamustine-rituximab then placebo or ibrutinib) were less effective treatment regimens. The Subcommittee considered that there was no clear evidence that ibrutinib conferred an additional benefit for patients with del11q above the general CLL population.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that ibrutinib with rituximab has reported favourable outcomes compared with FCR in patients with the del11q mutation (HR: 0.24; 95% CI: 0.10-0.62), however that this does not appear to differ substantially compared with all patients (HR:0.35, 95% CI: 0.22-0.56) (<a href=""https://www.nejm.org/doi/pdf/10.1056/NEJMoa1817073?articleTools=true"" target=""_blank"">Shanafelt et al. N Engl J Med. 2019;381:432-43</a>). The Subcommittee also noted that compared with bendamustine-rituximab, patients with del17 or del11q treated with ibrutinib were less likely to experience disease progression or death (HR: 0.26; 95% CI: 0.12-0.56) (<a href=""https://www.nejm.org/doi/pdf/10.1056/NEJMoa1817073?articleTools=true"" target=""_blank"">Shanafelt et al. N Engl J Med. 2019;381:432-43</a>). The Subcommittee noted that this result was also similar to the benefit observed in all patients in the study (HR: 0.37; 95% CI: 0.25-0.56).</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that testing for the del11q mutation (FISH) is routinely offered by all New Zealand District Health Boards. The Subcommittee considered that del17p, TP53 and IGHV mutational status are more significant prognostic risk factors than del11q.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there is emerging evidence that the residual ATM allele, located on chromosome 11q may be responsible for<i> </i>some of the adversity experienced by these patients, and considered that differentiating the del 11q subgroup from the wider population may be inappropriate as del 11q may be an oversimplification of a determinant of cellular response to treatment.\xa0</p><p style=""text-align: justify;""><br></p><p><br></p>', 'fs': '<p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that the current treatment options for patients ineligible for fludarabine based chemoimmunotherapy (fludarabine ± cyclophosphamide and rituximab) were obinutuzumab-chlorambucil or bendamustine-rituximab, and noted that bendamustine-rituximab was not funded in the relapsed/refractory setting. The Subcommittee noted that if the patient had the 17p deletion or the TP53 mutation, that they would be eligible for venetoclax monotherapy as first line treatment. The Subcommittee noted that patients who relapse within 36 months of treatment with obinutuzumab-chlorambucil or bendamustine-rituximab would be eligible for venetoclax-rituximab. The Subcommittee noted that after venetoclax-rituximab, if patients have not received obinutuzumab, they would be eligible for this as third line treatment.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the current treatment options for patients eligible for fludarabine based chemoimmunotherapy (fludarabine ± cyclophosphamide and rituximab) was FCR, unless the patient had the 17p deletion or the TP53 mutation, in which case they would be eligible for venetoclax monotherapy. The Subcommittee noted that that patients who relapse within 36 months of treatment with FCR would be eligible for venetoclax-rituximab. The Subcommittee noted that after venetoclax-rituximab, if patients have not received obinutuzumab, they would be eligible for this as third line treatment.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><i>Ibrutinib for patients with relapsed/refractory del11q CLL</i></p><p style=""text-align: justify;""><span style=""color: black;"">1.3</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the current Special Authority for venetoclax in combination with rituximab includes patients with relapsed/refractory del 11q CLL. The Subcommittee noted that ibrutinib has not been specifically reviewed in this subpopulation previously.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the del11q mutation is present in 10-20% of patients with CLL, and that patients with del11q were considered to have shorter progression free survival (i.e. faster progression) that those without. The Subcommittee noted that data from the CLL8 trial reported this risk of faster progression is reversed with immunochemotherapy (<a href=""https://ashpublications.org/blood/article/127/2/208/34815/Long-term-remissions-after-FCR-chemoimmunotherapy"" target=""_blank"">Fischer et al. Blood. 2016;127:208-15</a>). The Subcommittee considered that, when treated with FCR, the overall survival of patients with the del11q mutation is not adversely reduced compared with patients with normal cytogenetics. The Subcommittee considered that there was little evidence that the del11q subgroup is a high risk subgroup with greater unmet health need when compared with the wider CLL population. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the results of a pooled analysis of the randomised RESONATE, RESONATE-2 and HELIOS trials, which reported that ibrutinib-treated patients with del11q had a significantly longer progression free survival than ibrutinib-treated patients without del11q (42-month progression free survival rate 70% vs. 65%, p=0.02) (<a href=""https://www.sciencedirect.com/science/article/pii/S2152265019303982?via%3Dihub"" target=""_blank"" style=""color: blue;"">Kipps et al.</a><a href=""https://www.sciencedirect.com/science/article/pii/S2152265019303982?via%3Dihub"" target=""_blank"" style=""color: windowtext;""> </a><a href=""https://www.sciencedirect.com/science/article/pii/S2152265019303982?via%3Dihub"" target=""_blank"" style=""color: blue;"">Clin Lymphoma Myeloma Leuk. 2019;19(11):715-22</a>). The Subcommittee noted that the comparators in these trials (ofatumumab, chlorambucil and bendamustine-rituximab then placebo or ibrutinib) were less effective treatment regimens. The Subcommittee considered that there was no clear evidence that ibrutinib conferred an additional benefit for patients with del11q above the general CLL population.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that ibrutinib with rituximab has reported favourable outcomes compared with FCR in patients with the del11q mutation (HR: 0.24; 95% CI: 0.10-0.62), however that this does not appear to differ substantially compared with all patients (HR:0.35, 95% CI: 0.22-0.56) (<a href=""https://www.nejm.org/doi/pdf/10.1056/NEJMoa1817073?articleTools=true"" target=""_blank"">Shanafelt et al. N Engl J Med. 2019;381:432-43</a>). The Subcommittee also noted that compared with bendamustine-rituximab, patients with del17 or del11q treated with ibrutinib were less likely to experience disease progression or death (HR: 0.26; 95% CI: 0.12-0.56) (<a href=""https://www.nejm.org/doi/pdf/10.1056/NEJMoa1817073?articleTools=true"" target=""_blank"">Shanafelt et al. N Engl J Med. 2019;381:432-43</a>). The Subcommittee noted that this result was also similar to the benefit observed in all patients in the study (HR: 0.37; 95% CI: 0.25-0.56).</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that testing for the del11q mutation (FISH) is routinely offered by all New Zealand District Health Boards. The Subcommittee considered that del17p, TP53 and IGHV mutational status are more significant prognostic risk factors than del11q.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there is emerging evidence that the residual ATM allele, located on chromosome 11q may be responsible for<i> </i>some of the adversity experienced by these patients, and considered that differentiating the del 11q subgroup from the wider population may be inappropriate as del 11q may be an oversimplification of a determinant of cellular response to treatment.\xa0</p><p style=""text-align: justify;""><br></p><p><br></p>', 'change': None}, 'Published_Application': {'s': '<p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that there were three interrelated applications for treatments for chronic lymphocytic leukaemia (CLL). The Subcommittee considered:</p><p style=""text-align: justify;"">1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>an application for ibrutinib for relapsed/refractory chronic lymphocytic leukaemia with or without del 11q mutation and previously untreated chronic lymphocytic leukaemia with del 17p mutation;</p><p style=""text-align: justify;""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>This included: patients intolerant to venetoclax; patients who progress on or relapse after treatment with venetoclax and patients unsuitable for treatment with venetoclax</p><p style=""text-align: justify;"">1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>an application for ibrutinib for previously untreated CLL for whom chemoimmunotherapy is inappropriate;</p><p style=""text-align: justify;"">1.1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>an application for venetoclax for previously untreated chronic lymphocytic leukaemia patients for whom fludarabine-based chemoimmunotherapy is inappropriate and who are immunoglobulin heavy chain variable region (IGHV) unmutated.</p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering these agenda items</p><p style=""text-align: justify;""><br></p><p><br></p>', 'fs': '<p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that there were three interrelated applications for treatments for chronic lymphocytic leukaemia (CLL). The Subcommittee considered:</p><p style=""text-align: justify;"">1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>an application for ibrutinib for relapsed/refractory chronic lymphocytic leukaemia with or without del 11q mutation and previously untreated chronic lymphocytic leukaemia with del 17p mutation;</p><p style=""text-align: justify;""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>This included: patients intolerant to venetoclax; patients who progress on or relapse after treatment with venetoclax and patients unsuitable for treatment with venetoclax</p><p style=""text-align: justify;"">1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>an application for ibrutinib for previously untreated CLL for whom chemoimmunotherapy is inappropriate;</p><p style=""text-align: justify;"">1.1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>an application for venetoclax for previously untreated chronic lymphocytic leukaemia patients for whom fludarabine-based chemoimmunotherapy is inappropriate and who are immunoglobulin heavy chain variable region (IGHV) unmutated.</p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering these agenda items</p><p style=""text-align: justify;""><br></p><p><br></p>', 'change': None}, 'PTAC_Comments': {'s': '<p><span style=""font-size: 13.3333px; font-family: Arial, sans-serif; color: rgb(62, 62, 60);"">PTAC noted and agreed with the Subcommittee’s recorded considerations and recommendations regarding\xa0this application.</span></p>', 'fs': '<p><span style=""font-size: 13.3333px; font-family: Arial, sans-serif; color: rgb(62, 62, 60);"">PTAC noted and agreed with the Subcommittee’s recorded considerations and recommendations regarding\xa0this application.</span></p>', 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2020', 'fs': 'Sep 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 3 July 2020.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 3 July 2020.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4j8M2AR'}, 'Id': 'a0POZ00000B4j8M2AR', 'Event_Date__c': '2020-09-29', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 3 July 2020.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Sep 2020', 'Published_Recommendation__c': '<p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee <b>recommended</b> ibrutinib for the treatment of relapsed/refractory del11q CLL be declined, within the context of treatment of malignancy.</p><p style=""text-align: justify;"">1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Subcommittee considered there to be no clear evidence that ibrutinib confers additional benefit in patients with the del11q mutation compared with the wider CLL patient population when making this recommendation.</p><p><br></p>', 'Published_Application__c': '<p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that there were three interrelated applications for treatments for chronic lymphocytic leukaemia (CLL). The Subcommittee considered:</p><p style=""text-align: justify;"">1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>an application for ibrutinib for relapsed/refractory chronic lymphocytic leukaemia with or without del 11q mutation and previously untreated chronic lymphocytic leukaemia with del 17p mutation;</p><p style=""text-align: justify;""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>This included: patients intolerant to venetoclax; patients who progress on or relapse after treatment with venetoclax and patients unsuitable for treatment with venetoclax</p><p style=""text-align: justify;"">1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>an application for ibrutinib for previously untreated CLL for whom chemoimmunotherapy is inappropriate;</p><p style=""text-align: justify;"">1.1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>an application for venetoclax for previously untreated chronic lymphocytic leukaemia patients for whom fludarabine-based chemoimmunotherapy is inappropriate and who are immunoglobulin heavy chain variable region (IGHV) unmutated.</p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering these agenda items</p><p style=""text-align: justify;""><br></p><p><br></p>', 'Published_Discussion__c': '<p style=""text-align: justify;""><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that the current treatment options for patients ineligible for fludarabine based chemoimmunotherapy (fludarabine ± cyclophosphamide and rituximab) were obinutuzumab-chlorambucil or bendamustine-rituximab, and noted that bendamustine-rituximab was not funded in the relapsed/refractory setting. The Subcommittee noted that if the patient had the 17p deletion or the TP53 mutation, that they would be eligible for venetoclax monotherapy as first line treatment. The Subcommittee noted that patients who relapse within 36 months of treatment with obinutuzumab-chlorambucil or bendamustine-rituximab would be eligible for venetoclax-rituximab. The Subcommittee noted that after venetoclax-rituximab, if patients have not received obinutuzumab, they would be eligible for this as third line treatment.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the current treatment options for patients eligible for fludarabine based chemoimmunotherapy (fludarabine ± cyclophosphamide and rituximab) was FCR, unless the patient had the 17p deletion or the TP53 mutation, in which case they would be eligible for venetoclax monotherapy. The Subcommittee noted that that patients who relapse within 36 months of treatment with FCR would be eligible for venetoclax-rituximab. The Subcommittee noted that after venetoclax-rituximab, if patients have not received obinutuzumab, they would be eligible for this as third line treatment.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><i>Ibrutinib for patients with relapsed/refractory del11q CLL</i></p><p style=""text-align: justify;""><span style=""color: black;"">1.3</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the current Special Authority for venetoclax in combination with rituximab includes patients with relapsed/refractory del 11q CLL. The Subcommittee noted that ibrutinib has not been specifically reviewed in this subpopulation previously.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the del11q mutation is present in 10-20% of patients with CLL, and that patients with del11q were considered to have shorter progression free survival (i.e. faster progression) that those without. The Subcommittee noted that data from the CLL8 trial reported this risk of faster progression is reversed with immunochemotherapy (<a href=""https://ashpublications.org/blood/article/127/2/208/34815/Long-term-remissions-after-FCR-chemoimmunotherapy"" target=""_blank"">Fischer et al. Blood. 2016;127:208-15</a>). The Subcommittee considered that, when treated with FCR, the overall survival of patients with the del11q mutation is not adversely reduced compared with patients with normal cytogenetics. The Subcommittee considered that there was little evidence that the del11q subgroup is a high risk subgroup with greater unmet health need when compared with the wider CLL population. </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the results of a pooled analysis of the randomised RESONATE, RESONATE-2 and HELIOS trials, which reported that ibrutinib-treated patients with del11q had a significantly longer progression free survival than ibrutinib-treated patients without del11q (42-month progression free survival rate 70% vs. 65%, p=0.02) (<a href=""https://www.sciencedirect.com/science/article/pii/S2152265019303982?via%3Dihub"" target=""_blank"" style=""color: blue;"">Kipps et al.</a><a href=""https://www.sciencedirect.com/science/article/pii/S2152265019303982?via%3Dihub"" target=""_blank"" style=""color: windowtext;""> </a><a href=""https://www.sciencedirect.com/science/article/pii/S2152265019303982?via%3Dihub"" target=""_blank"" style=""color: blue;"">Clin Lymphoma Myeloma Leuk. 2019;19(11):715-22</a>). The Subcommittee noted that the comparators in these trials (ofatumumab, chlorambucil and bendamustine-rituximab then placebo or ibrutinib) were less effective treatment regimens. The Subcommittee considered that there was no clear evidence that ibrutinib conferred an additional benefit for patients with del11q above the general CLL population.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that ibrutinib with rituximab has reported favourable outcomes compared with FCR in patients with the del11q mutation (HR: 0.24; 95% CI: 0.10-0.62), however that this does not appear to differ substantially compared with all patients (HR:0.35, 95% CI: 0.22-0.56) (<a href=""https://www.nejm.org/doi/pdf/10.1056/NEJMoa1817073?articleTools=true"" target=""_blank"">Shanafelt et al. N Engl J Med. 2019;381:432-43</a>). The Subcommittee also noted that compared with bendamustine-rituximab, patients with del17 or del11q treated with ibrutinib were less likely to experience disease progression or death (HR: 0.26; 95% CI: 0.12-0.56) (<a href=""https://www.nejm.org/doi/pdf/10.1056/NEJMoa1817073?articleTools=true"" target=""_blank"">Shanafelt et al. N Engl J Med. 2019;381:432-43</a>). The Subcommittee noted that this result was also similar to the benefit observed in all patients in the study (HR: 0.37; 95% CI: 0.25-0.56).</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that testing for the del11q mutation (FISH) is routinely offered by all New Zealand District Health Boards. The Subcommittee considered that del17p, TP53 and IGHV mutational status are more significant prognostic risk factors than del11q.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there is emerging evidence that the residual ATM allele, located on chromosome 11q may be responsible for<i> </i>some of the adversity experienced by these patients, and considered that differentiating the del 11q subgroup from the wider population may be inappropriate as del 11q may be an oversimplification of a determinant of cellular response to treatment.\xa0</p><p style=""text-align: justify;""><br></p><p><br></p>', 'PTAC_Comments__c': '<p><span style=""font-size: 13.3333px; font-family: Arial, sans-serif; color: rgb(62, 62, 60);"">PTAC noted and agreed with the Subcommittee’s recorded considerations and recommendations regarding\xa0this application.</span></p>', 'Status_History__c': 'a132P000000CDC8QAO'}, 'change': None}]",Jun 2020,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2021', 'fs': 'May 2021', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4j8N2AR'}, 'Id': 'a0POZ00000B4j8N2AR', 'Event_Date__c': '2021-05-06', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2021', 'Status_History__c': 'a132P000000CpBJQA0'}, 'change': None}]",May 2021,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2021', 'fs': 'Jun 2021', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4j8O2AR'}, 'Id': 'a0POZ00000B4j8O2AR', 'Event_Date__c': '2021-06-09', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2021', 'Status_History__c': 'a132P000000CuomQAC'}, 'change': None}]",Jun 2021,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2"" target=""_blank"">Consultation notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2"" target=""_blank"">Consultation notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Dec 2023', 'fs': 'Dec 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4j8P2AR'}, 'Id': 'a0POZ00000B4j8P2AR', 'Event_Date__c': '2023-12-18', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2"" target=""_blank"">Consultation notification</a></p>', 'Formatted_Date__c': 'Dec 2023', 'Status_History__c': 'a13OZ000004kd46YAA'}, 'change': None}]",Dec 2023,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2024', 'fs': 'Feb 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4j8Q2AR'}, 'Id': 'a0POZ00000B4j8Q2AR', 'Event_Date__c': '2024-02-12', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Feb 2024', 'Status_History__c': 'a13OZ000006m3xqYAA'}, 'change': None}]",Feb 2024,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24"" target=""_blank"">Decision notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24"" target=""_blank"">Decision notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Jul 2024', 'fs': 'Jul 2024', 'change': None}, 'Event_Description': {'s': 'The funding application has been declined.', 'fs': 'The funding application has been declined.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4j8R2AR'}, 'Id': 'a0POZ00000B4j8R2AR', 'Event_Date__c': '2024-07-29', 'Event_Description__c': 'The funding application has been declined.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24"" target=""_blank"">Decision notification</a></p>', 'Formatted_Date__c': 'Jul 2024', 'Status_History__c': 'a13OZ00000CfrnpYAB'}, 'change': None}]",Jul 2024,False,True
